Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers.

[1]  M. Bendandi.  Anti-idiotype vaccines for human follicular lymphoma , 2000, Leukemia.

[2]  G. Martinelli,et al.  Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. , 2000, Blood.

[3]  G. Martinelli,et al.  Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Gribben,et al.  Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies , 2000, Nature Medicine.

[5]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[6]  T. Hamblin,et al.  DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma , 1998, Nature Medicine.

[7]  R. Levy,et al.  Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. , 1998, Blood.

[8]  J. Fagerberg,et al.  Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. , 1998, Blood.

[9]  S. Levy,et al.  Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. , 1997, Blood.

[10]  D. Czerwinski,et al.  Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. , 1997, Blood.

[11]  F. Hsu,et al.  Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. , 1995, Blood.

[12]  R. Braylan,et al.  Optimal primer selection for clonality assessment by polymerase chain reaction analysis: I. Low grade B-cell lymphoproliferative disorders of nonfollicular center cell type. , 1994, Human pathology.

[13]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[14]  G. Winter,et al.  Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. , 1994, Blood.

[15]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[16]  I. Sanz,et al.  Multiple mechanisms participate in the generation of diversity of human H chain CDR3 regions. , 1991, Journal of immunology.

[17]  W. Carroll,et al.  Mouse x human heterohybridomas as fusion partners with human B cell tumors. , 1986, Journal of immunological methods.

[18]  Preferential Use of the VH 4 Ig Gene Family by Diffuse Large-Cell Lymphoma , 2002 .

[19]  G. Martinelli,et al.  Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. , 2000, Haematologica.

[20]  H. Devereux.  Automated DNA sequencing. , 1999, Methods in molecular medicine.

[21]  L. Kwak,et al.  Development of vaccine strategies for the treatment of B-cell malignancies. , 1997, Cancer investigation.

[22]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.